• LAST PRICE
    0.3771
  • TODAY'S CHANGE (%)
    Trending Down-0.0129 (-3.3077%)
  • Bid / Lots
    0.3790/ 25
  • Ask / Lots
    0.4080/ 10
  • Open / Previous Close
    0.3950 / 0.3900
  • Day Range
    Low 0.3600
    High 0.3950
  • 52 Week Range
    Low 0.2701
    High 1.2600
  • Volume
    104,006
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.39
TimeVolumeSNTI
09:43 ET20010.3832
09:48 ET32650.38
09:56 ET5940.3801
09:59 ET118270.38
10:28 ET208950.36
10:30 ET15000.36001
10:44 ET226310.36
10:55 ET21010.37
11:56 ET5000.387
12:18 ET2500.3931
12:57 ET35000.374101
02:15 ET1680.3829
02:45 ET9000.3741
02:47 ET2500.375
03:23 ET20670.39
03:27 ET90500.39
03:32 ET139020.374
03:38 ET30560.3733
03:43 ET1000.3763
03:48 ET2000.388
03:57 ET2370.3878
03:59 ET4000.3771
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSNTI
Senti Biosciences Inc
17.3M
-0.2x
---
United StatesSYBX
Synlogic Inc
20.8M
-0.2x
---
United StatesLUMO
Lumos Pharma Inc
22.9M
-0.7x
---
United StatesADXN
Addex Therapeutics Ltd
19.5M
0.0x
---
United StatesOPGN
OpGen Inc
7.0M
-0.1x
---
United StatesXBIO
Xenetic Biosciences Inc
5.8M
-1.4x
---
As of 2024-03-29

Company Information

Senti Biosciences, Inc. is a clinical-stage biotechnology company. It is developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. It is focused on off-the-shelf CAR-NK cell therapy programs for oncology indications. Its lead product candidate, SENTI-202, is a potential Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia, while sparing healthy bone marrow cells. Its second clinical development program is SENTI-301A, a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy. SENTI-202 has been designed to incorporate three chimeric proteins using a Logic Gated gene circuit and delivered through a single retrovirus. SENTI-301A is a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy designed for the treatment of advanced GPC3 positive tumors.

Contact Information

Headquarters
2 Corporate Drive, First FloorSOUTH SAN FRANCISCO, CA, United States 94080
Phone
650-382-3281
Fax
302-655-5049

Executives

President, Chief Executive Officer, Director
Timothy Lu
Chief Financial Officer, Treasurer, Head - Corporate Development
Deborah Knobelman
Chief Executive Officer - GeneFab
Philip Lee
Head - Research and Development, Chief Medical Officer
Kanya Rajangam
Independent Director
Susan Berland

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$17.3M
Revenue (TTM)
$2.6M
Shares Outstanding
45.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.09
Book Value
$1.46
P/E Ratio
-0.2x
Price/Sales (TTM)
6.7
Price/Cash Flow (TTM)
---
Operating Margin
-3,984.50%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.